Last reviewed 2026-05-30 · How we verify

Telatinib Mesylate

Taizhou EOC Pharma Co., Ltd. · Phase 1 active Small molecule ✓ Verified May 2026

Telatinib Mesylate is a Small molecule drug developed by Taizhou EOC Pharma Co., Ltd.. It is currently in Phase 1 development. Also known as: BAY 57-9352, TEL0805, EOC315.

Telatinib Mesylate is a small molecule inhibitor that targets the stem cell growth factor receptor Kit. It is being studied in a Phase I clinical trial for the treatment of advanced solid tumors.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Telatinib Mesylate
Also known as	BAY 57-9352, TEL0805, EOC315
Sponsor	Taizhou EOC Pharma Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Telatinib Mesylate CI brief — competitive landscape report
Telatinib Mesylate updates RSS · CI watch RSS
Taizhou EOC Pharma Co., Ltd. portfolio CI

Frequently asked questions about Telatinib Mesylate

What is Telatinib Mesylate?

Telatinib Mesylate is a Small molecule drug developed by Taizhou EOC Pharma Co., Ltd..

Who makes Telatinib Mesylate?

Telatinib Mesylate is developed by Taizhou EOC Pharma Co., Ltd. (see full Taizhou EOC Pharma Co., Ltd. pipeline at /company/taizhou-eoc-pharma-co-ltd).

Is Telatinib Mesylate also known as anything else?

Telatinib Mesylate is also known as BAY 57-9352, TEL0805, EOC315.

What development phase is Telatinib Mesylate in?

Telatinib Mesylate is in Phase 1.

Manufacturer: Taizhou EOC Pharma Co., Ltd. — full pipeline
Also known as: BAY 57-9352, TEL0805, EOC315

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing